{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:08:53Z","timestamp":1789157333659,"version":"build-2803163510"},"reference-count":235,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematological malignancies (HM) represent a subset of neoplasms affecting the blood, bone marrow, and lymphatic systems, categorized primarily into leukemia, lymphoma, and multiple myeloma. Their prognosis varies considerably, with a frequent risk of relapse despite ongoing treatments. While contemporary therapeutic strategies have extended overall patient survival, they do not offer cures for advanced stages and often lead to challenges such as acquisition of drug resistance, recurrence, and severe side effects. The need for innovative therapeutic targets is vital to elevate both survival rates and patients' quality of life. Recent research has pivoted towards nuclear receptors (NRs) due to their role in modulating tumor cell characteristics including uncontrolled proliferation, differentiation, apoptosis evasion, invasion and\u00a0migration. Existing evidence emphasizes NRs' critical role in HM. The regulation of NR expression through agonists, antagonists, or selective modulators, contingent upon their levels, offers promising clinical implications in HM management. Moreover, several anticancer agents targeting NRs have been approved by the Food and Drug Administration (FDA). This review highlights the integral function of NRs in HM's pathophysiology and the potential benefits of therapeutically targeting these receptors, suggesting a prospective avenue for more efficient therapeutic interventions against HM.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00018-023-05085-z","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:02:26Z","timestamp":1707454946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Exploring the nexus of nuclear receptors in hematological malignancies"],"prefix":"10.1007","volume":"81","author":[{"given":"Mukesh Kumar","family":"Manickasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandari","family":"BharathwajChetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu Santha","family":"Aswani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Shakibaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-8475","authenticated-orcid":false,"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaikumar B.","family":"Kunnumakkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"4","key":"5085_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","volume":"130","author":"J Taylor","year":"2017","unstructured":"Taylor J, Xiao W, Abdel-Wahab O (2017) Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood 130(4):410\u2013423. https:\/\/doi.org\/10.1182\/blood-2017-02-734541","journal-title":"Blood"},{"issue":"48","key":"5085_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7748\/ns.30.48.15.s16","volume":"30","author":"L Pearce","year":"2016","unstructured":"Pearce L (2016) Haematological cancers. Nurs Stand 30(48):15. https:\/\/doi.org\/10.7748\/ns.30.48.15.s16","journal-title":"Nurs Stand"},{"issue":"4","key":"5085_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.pop.2016.07.012","volume":"43","author":"EN Mugnaini","year":"2016","unstructured":"Mugnaini EN, Ghosh N (2016) Lymphoma. Prim Care 43(4):661\u2013675. https:\/\/doi.org\/10.1016\/j.pop.2016.07.012","journal-title":"Prim Care"},{"issue":"27\u201328","key":"5085_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3238\/arztebl.2016.0470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S (2016) The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int 113(27\u201328):470\u2013476. https:\/\/doi.org\/10.3238\/arztebl.2016.0470","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"5085_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","volume":"8","author":"A Zhao","year":"2023","unstructured":"Zhao A, Zhou H, Yang J, Li M, Niu T (2023) Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct Target Ther 8(1):71. https:\/\/doi.org\/10.1038\/s41392-023-01342-6","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"5085_CR6","first-page":"454","volume":"8","author":"S Zebardast","year":"2020","unstructured":"Zebardast S, Sahmani M, Mohammadi S, Foroughi F, Dehghani Fard A, Mohammadi Z et al (2020) The gene expression profile and DNA methylation pattern of CDH1 and DNMT1 genes in acute promyelocytic leukemia (APL). Rep Biochem Mol Biol 8(4):454\u2013457","journal-title":"Rep Biochem Mol Biol"},{"issue":"5","key":"5085_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.trecan.2017.04.004","volume":"3","author":"EN Wainwright","year":"2017","unstructured":"Wainwright EN, Scaffidi P (2017) Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer 3(5):372\u2013386. https:\/\/doi.org\/10.1016\/j.trecan.2017.04.004","journal-title":"Trends Cancer"},{"key":"5085_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2021.100024","volume":"4","author":"YX Torres-Llanos","year":"2022","unstructured":"Torres-Llanos YX, Combita-Rojas AL (2022) Relation between tumor micro-environment and epigenetic alterations in hematological malignancies. Adv Cancer Biol-Metastasis 4:100024","journal-title":"Adv Cancer Biol-Metastasis"},{"issue":"47","key":"5085_CR9","doi-asserted-by":"publisher","first-page":"43491","DOI":"10.1074\/jbc.C100532200","volume":"276","author":"MM Khan","year":"2001","unstructured":"Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Zhong S et al (2001) PML-RARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb. J Biol Chem 276(47):43491\u201343494. https:\/\/doi.org\/10.1074\/jbc.C100532200","journal-title":"J Biol Chem"},{"issue":"12","key":"5085_CR10","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.1128\/MCB.18.12.7185","volume":"18","author":"V Gelmetti","year":"1998","unstructured":"Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18(12):7185\u20137191. https:\/\/doi.org\/10.1128\/MCB.18.12.7185","journal-title":"Mol Cell Biol"},{"issue":"17","key":"5085_CR11","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.3390\/ijms21176091","volume":"21","author":"P Auberger","year":"2020","unstructured":"Auberger P, Tamburini-Bonnefoy J, Puissant A (2020) Drug resistance in hematological malignancies. Int J Mol Sci 21(17):6091. https:\/\/doi.org\/10.3390\/ijms21176091","journal-title":"Int J Mol Sci"},{"key":"5085_CR12","doi-asserted-by":"publisher","DOI":"10.1142\/7150","volume-title":"Molecular targets and therapeutic uses of spices: modern uses for ancient medicine","author":"BB Aggarwal","year":"2009","unstructured":"Aggarwal BB, Kunnumakkara AB (2009) Molecular targets and therapeutic uses of spices: modern uses for ancient medicine. World Scientific"},{"key":"5085_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118814","volume":"267","author":"SA Ahmed","year":"2021","unstructured":"Ahmed SA, Parama D, Daimari E, Girisa S, Banik K, Harsha C et al (2021) Rationalizing the therapeutic potential of apigenin against cancer. Life Sci 267:118814","journal-title":"Life Sci"},{"issue":"11","key":"5085_CR14","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.31557\/APJCP.2019.20.11.3437","volume":"20","author":"D Bordoloi","year":"2019","unstructured":"Bordoloi D, Monisha J, Roy M, Padmavathi G, Banik K, Harsha C et al (2019) An investigation on the therapeutic potential of butein, a tretrahydroxychalcone against human oral squamous cell carcinoma. Asian Pac J Cancer Prev APJCP 20(11):3437","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"5085_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650603","volume":"11","author":"C Buhrmann","year":"2021","unstructured":"Buhrmann C, Kunnumakkara AB, Kumar A, Samec M, Kubatka P, Aggarwal BB et al (2021) Multitargeting effects of calebin A on malignancy of CRC cells in multicellular tumor microenvironment. Front Oncol 11:650603. https:\/\/doi.org\/10.3389\/fonc.2021.650603","journal-title":"Front Oncol"},{"issue":"12","key":"5085_CR16","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/nu11122904","volume":"11","author":"C Buhrmann","year":"2019","unstructured":"Buhrmann C, Popper B, Kunnumakkara AB, Aggarwal BB, Shakibaei M (2019) Evidence that Calebin A, a component of curcuma longa suppresses NF-\u03baB mediated proliferation, invasion and metastasis of human colorectal cancer induced by TNF-\u03b2 (Lymphotoxin). Nutrients 11(12):2904","journal-title":"Nutrients"},{"issue":"2","key":"5085_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22950","volume":"36","author":"U Devi Daimary","year":"2022","unstructured":"Devi Daimary U, Girisa S, Parama D, Verma E, Kumar A, Kunnumakkara AB (2022) Embelin: a novel XIAP inhibitor for the prevention and treatment of chronic diseases. J Biochem Mol Toxicol 36(2):e22950","journal-title":"J Biochem Mol Toxicol"},{"key":"5085_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.37349\/etat.2020.00019","volume":"1","author":"S Girisa","year":"2020","unstructured":"Girisa S, Parama D, Harsha C, Banik K, Kunnumakkara AB (2020) Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer. Explor Target Antitumor Ther 1:313\u2013342","journal-title":"Explor Target Antitumor Ther"},{"issue":"4","key":"5085_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/molecules24040734","volume":"24","author":"S Girisa","year":"2019","unstructured":"Girisa S, Shabnam B, Monisha J, Fan L, Halim CE, Arfuso F et al (2019) Potential of zerumbone as an anti-cancer agent. Molecules 24(4):734. https:\/\/doi.org\/10.3390\/molecules24040734","journal-title":"Molecules"},{"key":"5085_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.fct.2017.07.023","volume":"108","author":"C Harsha","year":"2017","unstructured":"Harsha C, Banik K, Bordoloi D, Kunnumakkara AB (2017) Antiulcer properties of fruits and vegetables: a mechanism based perspective. Food Chem Toxicol 108:104\u2013119. https:\/\/doi.org\/10.1016\/j.fct.2017.07.023","journal-title":"Food Chem Toxicol"},{"key":"5085_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-022-10068-w","author":"M Hegde","year":"2022","unstructured":"Hegde M, Girisa S, Naliyadhara N, Kumar A, Alqahtani MS, Abbas M et al (2022) Natural compounds targeting nuclear receptors for effective cancer therapy. Cancer Metastasis Rev. https:\/\/doi.org\/10.1007\/s10555-022-10068-w","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"5085_CR22","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/molecules25102278","volume":"25","author":"S Henamayee","year":"2020","unstructured":"Henamayee S, Banik K, Sailo BL, Shabnam B, Harsha C, Srilakshmi S et al (2020) Therapeutic emergence of rhein as a potential anticancer drug: a review of its molecular targets and anticancer properties. Molecules 25(10):2278","journal-title":"Molecules"},{"key":"5085_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3389\/fphar.2018.00686","volume":"9","author":"AB Kunnumakkara","year":"2018","unstructured":"Kunnumakkara AB, Banik K, Bordoloi D, Harsha C, Sailo BL, Padmavathi G et al (2018) Googling the Guggul (Commiphora and Boswellia) for prevention of chronic diseases. Front Pharmacol 9:686","journal-title":"Front Pharmacol"},{"key":"5085_CR24","first-page":"1","volume-title":"Molecular targets and therapeutic uses of spices: modern uses for ancient medicine","author":"AB Kunnumakkara","year":"2009","unstructured":"Kunnumakkara AB, Koca C, Dey S, Gehlot P, Yodkeeree S, Danda D et al (2009) Traditional uses of spices: an overview. Molecular targets and therapeutic uses of spices: modern uses for ancient medicine. World Scientific, pp 1\u201324"},{"issue":"12","key":"5085_CR25","first-page":"5112","volume":"109","author":"AB Kunnumakkara","year":"2007","unstructured":"Kunnumakkara AB, Nair AS, Ahn KS, Pandey MK, Yi Z, Liu M et al (2007) Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-\u03baB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. Blood, J Am Soc Hematol 109(12):5112\u20135121","journal-title":"Blood, J Am Soc Hematol"},{"issue":"3","key":"5085_CR26","doi-asserted-by":"publisher","first-page":"E292","DOI":"10.1002\/ijc.26442","volume":"131","author":"AB Kunnumakkara","year":"2012","unstructured":"Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S et al (2012) Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer 131(3):E292-303. https:\/\/doi.org\/10.1002\/ijc.26442","journal-title":"Int J Cancer"},{"issue":"5","key":"5085_CR27","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/pros.20899","volume":"69","author":"SB Muralimanoharan","year":"2009","unstructured":"Muralimanoharan SB, Kunnumakkara AB, Shylesh B, Kulkarni KH, Haiyan X, Ming H et al (2009) Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate 69(5):494\u2013504. https:\/\/doi.org\/10.1002\/pros.20899","journal-title":"Prostate"},{"issue":"1","key":"5085_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/biom9010013","volume":"9","author":"A Nair","year":"2019","unstructured":"Nair A, Amalraj A, Jacob J, Kunnumakkara AB, Gopi S (2019) Non-curcuminoids from turmeric and their potential in cancer therapy and anticancer drug delivery formulations. Biomolecules 9(1):13","journal-title":"Biomolecules"},{"issue":"13","key":"5085_CR29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.phymed.2015.08.015","volume":"22","author":"G Padmavathi","year":"2015","unstructured":"Padmavathi G, Rathnakaram SR, Monisha J, Bordoloi D, Roy NK, Kunnumakkara AB (2015) Potential of butein, a tetrahydroxychalcone to obliterate cancer. Phytomedicine 22(13):1163\u20131171","journal-title":"Phytomedicine"},{"key":"5085_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.phymed.2016.12.002","volume":"25","author":"G Padmavathi","year":"2017","unstructured":"Padmavathi G, Roy NK, Bordoloi D, Arfuso F, Mishra S, Sethi G et al (2017) Butein in health and disease: a comprehensive review. Phytomedicine 25:118\u2013127","journal-title":"Phytomedicine"},{"key":"5085_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154369","volume":"105","author":"A Sajeev","year":"2022","unstructured":"Sajeev A, Hegde M, Daimary UD, Kumar A, Girisa S, Sethi G et al (2022) Modulation of diverse oncogenic signaling pathways by oroxylin A: an important strategy for both cancer prevention and treatment. Phytomedicine 105:154369. https:\/\/doi.org\/10.1016\/j.phymed.2022.154369","journal-title":"Phytomedicine"},{"issue":"9","key":"5085_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/biom12091185","volume":"12","author":"A Sajeev","year":"2022","unstructured":"Sajeev A, Hegde M, Girisa S, Devanarayanan TN, Alqahtani MS, Abbas M et al (2022) Oroxylin A: a promising flavonoid for prevention and treatment of chronic diseases. Biomolecules 12(9):1185. https:\/\/doi.org\/10.3390\/biom12091185","journal-title":"Biomolecules"},{"key":"5085_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2021.104660","volume":"86","author":"E Verma","year":"2021","unstructured":"Verma E, Kumar A, Devi Daimary U, Parama D, Girisa S, Sethi G et al (2021) Potential of baicalein in the prevention and treatment of cancer: a scientometric analyses based review. J Funct Foods 86:104660. https:\/\/doi.org\/10.1016\/j.jff.2021.104660","journal-title":"J Funct Foods"},{"issue":"9","key":"5085_CR34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bph.13751","volume":"174","author":"W Hu","year":"2017","unstructured":"Hu W, Deng C, Ma Z, Wang D, Fan C, Li T et al (2017) Utilizing melatonin to combat bacterial infections and septic injury. Br J Pharmacol 174(9):754\u2013768. https:\/\/doi.org\/10.1111\/bph.13751","journal-title":"Br J Pharmacol"},{"issue":"3","key":"5085_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"5085_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nrg.2017.102","volume":"19","author":"VK Dhiman","year":"2018","unstructured":"Dhiman VK, Bolt MJ, White KP (2018) Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. Nat Rev Genet 19(3):160\u2013174. https:\/\/doi.org\/10.1038\/nrg.2017.102","journal-title":"Nat Rev Genet"},{"issue":"9","key":"5085_CR37","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.3390\/cells9091921","volume":"9","author":"P Pan","year":"2020","unstructured":"Pan P, Chen X (2020) Nuclear receptors as potential therapeutic targets for myeloid leukemia. Cells 9(9):1921. https:\/\/doi.org\/10.3390\/cells9091921","journal-title":"Cells"},{"issue":"18","key":"5085_CR38","doi-asserted-by":"publisher","first-page":"10952","DOI":"10.3390\/ijms231810952","volume":"23","author":"S Jayaprakash","year":"2022","unstructured":"Jayaprakash S, Hegde M, Girisa S, Alqahtani MS, Abbas M, Lee EHC et al (2022) Demystifying the functional role of nuclear receptors in esophageal cancer. Int J Mol Sci 23(18):10952. https:\/\/doi.org\/10.3390\/ijms231810952","journal-title":"Int J Mol Sci"},{"key":"5085_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9195-2_1","volume":"1966","author":"GI Mazaira","year":"2019","unstructured":"Mazaira GI, Zgajnar NR, Lotufo CM, Daneri-Becerra C, Sivils JC, Soto OB et al (2019) Nuclear receptors: a historical perspective. Methods Mol Biol 1966:1\u20135. https:\/\/doi.org\/10.1007\/978-1-4939-9195-2_1","journal-title":"Methods Mol Biol"},{"issue":"1","key":"5085_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s43556-021-00035-2","volume":"2","author":"S Girisa","year":"2021","unstructured":"Girisa S, Henamayee S, Parama D, Rana V, Dutta U, Kunnumakkara AB (2021) Targeting farnesoid X receptor (FXR) for developing novel therapeutics against cancer. Mol Biomed 2(1):21. https:\/\/doi.org\/10.1186\/s43556-021-00035-2","journal-title":"Mol Biomed"},{"issue":"6","key":"5085_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbamcr.2009.11.012","volume":"1803","author":"PC Echeverria","year":"2010","unstructured":"Echeverria PC, Picard D (2010) Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim Biophys Acta 1803(6):641\u2013649. https:\/\/doi.org\/10.1016\/j.bbamcr.2009.11.012","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"5085_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1101\/gad.14.2.121","volume":"14","author":"CK Glass","year":"2000","unstructured":"Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14(2):121\u2013141","journal-title":"Genes Dev"},{"issue":"3","key":"5085_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1021\/bi101762x","volume":"50","author":"YA Bulynko","year":"2011","unstructured":"Bulynko YA, O\u2019Malley BW (2011) Nuclear receptor coactivators: structural and functional biochemistry. Biochemistry 50(3):313\u2013328. https:\/\/doi.org\/10.1021\/bi101762x","journal-title":"Biochemistry"},{"issue":"3","key":"5085_CR44","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016709","volume":"5","author":"R Sever","year":"2013","unstructured":"Sever R, Glass CK (2013) Signaling by nuclear receptors. Cold Spring Harb Perspect Biol 5(3):a016709. https:\/\/doi.org\/10.1101\/cshperspect.a016709","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6548","key":"5085_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/377454a0","volume":"377","author":"JD Chen","year":"1995","unstructured":"Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377(6548):454\u2013457. https:\/\/doi.org\/10.1038\/377454a0","journal-title":"Nature"},{"issue":"6548","key":"5085_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/377397a0","volume":"377","author":"AJ Horlein","year":"1995","unstructured":"Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R et al (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377(6548):397\u2013404. https:\/\/doi.org\/10.1038\/377397a0","journal-title":"Nature"},{"issue":"2","key":"5085_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.mce.2011.08.033","volume":"348","author":"PJ Watson","year":"2012","unstructured":"Watson PJ, Fairall L, Schwabe JW (2012) Nuclear hormone receptor co-repressors: structure and function. Mol Cell Endocrinol 348(2):440\u2013449. https:\/\/doi.org\/10.1016\/j.mce.2011.08.033","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"5085_CR48","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-x","volume":"83","author":"DJ Mangelsdorf","year":"1995","unstructured":"Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al (1995) The nuclear receptor superfamily: the second decade. Cell 83(6):835\u2013839. https:\/\/doi.org\/10.1016\/0092-8674(95)90199-x","journal-title":"Cell"},{"key":"5085_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.apcsb.2021.02.006","volume":"126","author":"S Girisa","year":"2021","unstructured":"Girisa S, Rana V, Parama D, Dutta U, Kunnumakkara AB (2021) Differential roles of farnesoid X receptor (FXR) in modulating apoptosis in cancer cells. Adv Protein Chem Struct Biol 126:63\u201390","journal-title":"Adv Protein Chem Struct Biol"},{"key":"5085_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215666","volume":"536","author":"SK Gangwar","year":"2022","unstructured":"Gangwar SK, Kumar A, Jose S, Alqahtani MS, Abbas M, Sethi G et al (2022) Nuclear receptors in oral cancer-emerging players in tumorigenesis. Cancer Lett 536:215666. https:\/\/doi.org\/10.1016\/j.canlet.2022.215666","journal-title":"Cancer Lett"},{"issue":"5","key":"5085_CR51","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/ph15050624","volume":"15","author":"SK Gangwar","year":"2022","unstructured":"Gangwar SK, Kumar A, Yap KC, Jose S, Parama D, Sethi G et al (2022) Targeting nuclear receptors in lung cancer-novel therapeutic prospects. Pharmaceuticals (Basel) 15(5):624. https:\/\/doi.org\/10.3390\/ph15050624","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"5085_CR52","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1210\/er.2018-00222","volume":"40","author":"L Zhao","year":"2019","unstructured":"Zhao L, Zhou S, Gustafsson JA (2019) Nuclear receptors: recent drug discovery for cancer therapies. Endocr Rev 40(5):1207\u20131249. https:\/\/doi.org\/10.1210\/er.2018-00222","journal-title":"Endocr Rev"},{"issue":"1","key":"5085_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2013.10.014","volume":"14","author":"CL Vogel","year":"2014","unstructured":"Vogel CL, Johnston MA, Capers C, Braccia D (2014) Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer 14(1):1\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2013.10.014","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"5085_CR54","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/OGX.0b013e31828baef9","volume":"68","author":"S Gizzo","year":"2013","unstructured":"Gizzo S, Saccardi C, Patrelli TS, Berretta R, Capobianco G, Di Gangi S et al (2013) Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv 68(6):467\u2013481. https:\/\/doi.org\/10.1097\/OGX.0b013e31828baef9","journal-title":"Obstet Gynecol Surv"},{"issue":"10","key":"5085_CR55","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1517\/14656566.2014.915313","volume":"15","author":"Z Culig","year":"2014","unstructured":"Culig Z (2014) Targeting the androgen receptor in prostate cancer. Expert Opin Pharmacother 15(10):1427\u20131437. https:\/\/doi.org\/10.1517\/14656566.2014.915313","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"5085_CR56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1042\/EBC20210020","volume":"65","author":"DE Frigo","year":"2021","unstructured":"Frigo DE, Bondesson M, Williams C (2021) Nuclear receptors: from molecular mechanisms to therapeutics. Essays Biochem 65(6):847\u2013856. https:\/\/doi.org\/10.1042\/EBC20210020","journal-title":"Essays Biochem"},{"issue":"10","key":"5085_CR57","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nrd2397","volume":"6","author":"L Altucci","year":"2007","unstructured":"Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6(10):793\u2013810. https:\/\/doi.org\/10.1038\/nrd2397","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5085_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5507\/bp.2007.033","volume":"151","author":"J Brtko","year":"2007","unstructured":"Brtko J (2007) Retinoids, rexinoids and their cognate nuclear receptors: character and their role in chemoprevention of selected malignant diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151(2):187\u2013194. https:\/\/doi.org\/10.5507\/bp.2007.033","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"8","key":"5085_CR59","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1590\/1806-9282.20210451","volume":"67","author":"A Norouzi","year":"2021","unstructured":"Norouzi A, Motaghi M, Hassanshahi G, Nazari-Robati M (2021) Exploring the expression profile of vitamin D receptor and its related long non-coding RNAs in patients with acute lymphoblastic leukemia. Rev Assoc Med Bras (1992) 67(8):1113\u20131117. https:\/\/doi.org\/10.1590\/1806-9282.20210451","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"5","key":"5085_CR60","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1007\/s11033-021-06463-1","volume":"48","author":"S Sana","year":"2021","unstructured":"Sana S, Kayani MA (2021) Role of vitamin D deficiency and mRNA expression of VDR and RXR in haematological cancers. Mol Biol Rep 48(5):4431\u20134439. https:\/\/doi.org\/10.1007\/s11033-021-06463-1","journal-title":"Mol Biol Rep"},{"issue":"9","key":"5085_CR61","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/cancers13092153","volume":"13","author":"HS Cheng","year":"2021","unstructured":"Cheng HS, Yip YS, Lim EKY, Wahli W, Tan NS (2021) PPARs and tumor microenvironment: the emerging roles of the metabolic master regulators in tumor stromal-epithelial crosstalk and carcinogenesis. Cancers (Basel) 13(9):2153. https:\/\/doi.org\/10.3390\/cancers13092153","journal-title":"Cancers (Basel)"},{"issue":"1\u20132","key":"5085_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000503995","volume":"7","author":"M Yaghoubizadeh","year":"2020","unstructured":"Yaghoubizadeh M, Pishkar L, Basati G (2020) Aberrant expression of peroxisome proliferator-activated receptors in colorectal cancer and their association with cancer progression and prognosis. Gastrointest Tumors 7(1\u20132):11\u201320. https:\/\/doi.org\/10.1159\/000503995","journal-title":"Gastrointest Tumors"},{"issue":"24","key":"5085_CR63","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.3390\/ijms21249721","volume":"21","author":"G Augimeri","year":"2020","unstructured":"Augimeri G, Gelsomino L, Plastina P, Giordano C, Barone I, Catalano S et al (2020) Natural and synthetic PPARgamma ligands in tumor microenvironment: a new potential strategy against breast cancer. Int J Mol Sci 21(24):9721. https:\/\/doi.org\/10.3390\/ijms21249721","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5085_CR64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/10428194.2011.605187","volume":"53","author":"K Yakimchuk","year":"2012","unstructured":"Yakimchuk K, Norin S, Kimby E, Hagglund H, Warner M, Gustafsson JA (2012) Up-regulated estrogen receptor beta2 in chronic lymphocytic leukemia. Leuk Lymphoma 53(1):139\u2013144. https:\/\/doi.org\/10.3109\/10428194.2011.605187","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5085_CR65","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-022-01372-7","volume":"15","author":"W Seo","year":"2022","unstructured":"Seo W, Yoo S, Zhong Y, Lee SH, Woo SY, Choi HS et al (2022) Targeting ERRalpha promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation. J Hematol Oncol 15(1):156. https:\/\/doi.org\/10.1186\/s13045-022-01372-7","journal-title":"J Hematol Oncol"},{"issue":"6","key":"5085_CR66","first-page":"805","volume":"51","author":"Y Guan","year":"2021","unstructured":"Guan Y, Si Y, Cai W, Ma L, Fang M (2021) The mRNA expression and regulation of glucocorticoid receptor isoforms associated with response of multiple myeloma treated with a glucocorticoids-dependent regimen of dexamethasone, bortezomib and thalidomide. Ann Clin Lab Sci 51(6):805\u2013817","journal-title":"Ann Clin Lab Sci"},{"issue":"4","key":"5085_CR67","first-page":"327","volume":"18","author":"M Nishikawa","year":"1988","unstructured":"Nishikawa M, Uemura Y, Komada F, Ohno T, Katayama N, Shirakawa S (1988) Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect. Jpn J Clin Oncol 18(4):327\u2013333","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"5085_CR68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4161\/cc.23048","volume":"12","author":"E Lesovaya","year":"2013","unstructured":"Lesovaya E, Yemelyanov A, Kirsanov K, Popa A, Belitsky G, Yakubovskaya M et al (2013) Combination of a selective activator of the glucocorticoid receptor compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. Cell Cycle 12(1):133\u2013144. https:\/\/doi.org\/10.4161\/cc.23048","journal-title":"Cell Cycle"},{"issue":"6","key":"5085_CR69","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.V58.6.1198.1198","volume":"58","author":"GF Shipman","year":"1981","unstructured":"Shipman GF, Bloomfield CD, Smith KA, Peterson BA, Munck A (1981) The effects of glucocorticoid therapy on glucocorticoid receptors in leukemia and lymphoma. Blood 58(6):1198\u20131202","journal-title":"Blood"},{"issue":"8","key":"5085_CR70","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41375-020-0748-6","volume":"34","author":"AM Wandler","year":"2020","unstructured":"Wandler AM, Huang BJ, Craig JW, Hayes K, Yan H, Meyer LK et al (2020) Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia 34(8):2025\u20132037. https:\/\/doi.org\/10.1038\/s41375-020-0748-6","journal-title":"Leukemia"},{"key":"5085_CR71","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.921649","volume":"26","author":"W Xu","year":"2020","unstructured":"Xu W, Wang Z, Li K, Jin R (2020) Huai Qi Huang potentiates dexamethasone-mediated lethality in acute lymphoblastic leukemia cells by upregulating glucocorticoid receptor alpha. Med Sci Monit 26:e921649. https:\/\/doi.org\/10.12659\/MSM.921649","journal-title":"Med Sci Monit"},{"issue":"5","key":"5085_CR72","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3967\/0895-3988.2013.05.006","volume":"26","author":"X Guo","year":"2013","unstructured":"Guo X, Zhou CY, Li Q, Gao J, Zhu YP, Gu L et al (2013) Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor. Biomed Environ Sci 26(5):371\u2013381. https:\/\/doi.org\/10.3967\/0895-3988.2013.05.006","journal-title":"Biomed Environ Sci"},{"issue":"16","key":"5085_CR73","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/1078-0432.CCR-07-0276","volume":"13","author":"JA Meyers","year":"2007","unstructured":"Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A (2007) Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res 13(16):4920\u20134927. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0276","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5085_CR74","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/s41467-017-01948-9","volume":"8","author":"G Segala","year":"2017","unstructured":"Segala G, David M, de Medina P, Poirot MC, Serhan N, Vergez F et al (2017) Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nat Commun 8(1):1903. https:\/\/doi.org\/10.1038\/s41467-017-01948-9","journal-title":"Nat Commun"},{"issue":"10","key":"5085_CR75","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.3390\/cancers12102933","volume":"12","author":"PL Mouchel","year":"2020","unstructured":"Mouchel PL, Serhan N, Betous R, Farge T, Saland E, De Medina P et al (2020) Dendrogenin A enhances anti-leukemic effect of anthracycline in acute myeloid leukemia. Cancers (Basel) 12(10):2933. https:\/\/doi.org\/10.3390\/cancers12102933","journal-title":"Cancers (Basel)"},{"issue":"6","key":"5085_CR76","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/leu.2012.366","volume":"27","author":"L Zhou","year":"2013","unstructured":"Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O et al (2013) HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia 27(6):1358\u20131368. https:\/\/doi.org\/10.1038\/leu.2012.366","journal-title":"Leukemia"},{"key":"5085_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153448","volume":"82","author":"C Wang","year":"2021","unstructured":"Wang C, Liu G, Dou G, Yang Y, Chen L, Ma H et al (2021) Z-Ligustilide selectively targets AML by restoring nuclear receptors Nur77 and NOR-1-mediated apoptosis and differentiation. Phytomedicine 82:153448. https:\/\/doi.org\/10.1016\/j.phymed.2020.153448","journal-title":"Phytomedicine"},{"key":"5085_CR78","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3389\/fphar.2020.01321","volume":"11","author":"Z Yu","year":"2020","unstructured":"Yu Z, Li L, Wang C, He H, Liu G, Ma H et al (2020) Cantharidin induces apoptosis and promotes differentiation of AML cells through nuclear receptor Nur77-mediated signaling pathway. Front Pharmacol 11:1321. https:\/\/doi.org\/10.3389\/fphar.2020.01321","journal-title":"Front Pharmacol"},{"issue":"2","key":"5085_CR79","first-page":"573","volume":"34","author":"HB Liu","year":"2009","unstructured":"Liu HB, Voso MT, Gumiero D, Duong J, McKendrick JJ, Dear AE (2009) The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. Int J Oncol 34(2):573\u2013579","journal-title":"Int J Oncol"},{"issue":"35","key":"5085_CR80","doi-asserted-by":"publisher","first-page":"7687","DOI":"10.1021\/acs.jafc.7b02299","volume":"65","author":"C Wang","year":"2017","unstructured":"Wang C, He H, Dou G, Li J, Zhang X, Jiang M et al (2017) Ginsenoside 20(S)-Rh2 induces apoptosis and differentiation of acute myeloid leukemia cells: role of orphan nuclear receptor Nur77. J Agric Food Chem 65(35):7687\u20137697. https:\/\/doi.org\/10.1021\/acs.jafc.7b02299","journal-title":"J Agric Food Chem"},{"issue":"6","key":"5085_CR81","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3892\/ijo.13.6.1263","volume":"13","author":"S Fujimura","year":"1998","unstructured":"Fujimura S, Suzumiya J, Nakamura K, Ono J (1998) Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int J Oncol 13(6):1263\u20131267. https:\/\/doi.org\/10.3892\/ijo.13.6.1263","journal-title":"Int J Oncol"},{"issue":"5","key":"5085_CR82","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.cdd.4401000","volume":"9","author":"N Yamakawa-Karakida","year":"2002","unstructured":"Yamakawa-Karakida N, Sugita K, Inukai T, Goi K, Nakamura M, Uno K et al (2002) Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ 9(5):513\u2013526. https:\/\/doi.org\/10.1038\/sj.cdd.4401000","journal-title":"Cell Death Differ"},{"issue":"3","key":"5085_CR83","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/annonc\/mdi077","volume":"16","author":"JJ Liu","year":"2005","unstructured":"Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Lin Q et al (2005) Expression of survivin and bax\/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol 16(3):455\u2013459. https:\/\/doi.org\/10.1093\/annonc\/mdi077","journal-title":"Ann Oncol"},{"issue":"3","key":"5085_CR84","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00277-006-0205-2","volume":"86","author":"JJ Liu","year":"2007","unstructured":"Liu JJ, Liu PQ, Lin DJ, Xiao RZ, Huang M, Li XD et al (2007) Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol 86(3):173\u2013183. https:\/\/doi.org\/10.1007\/s00277-006-0205-2","journal-title":"Ann Hematol"},{"issue":"7","key":"5085_CR85","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/0008-5472.CAN-04-3781","volume":"65","author":"R Contractor","year":"2005","unstructured":"Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH et al (2005) A novel ring-substituted diindolylmethane,1,1-bis[3\u2019-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res 65(7):2890\u20132898. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3781","journal-title":"Cancer Res"},{"issue":"7","key":"5085_CR86","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1158\/1535-7163.MCT-06-0023","volume":"5","author":"S Nakata","year":"2006","unstructured":"Nakata S, Yoshida T, Shiraishi T, Horinaka M, Kouhara J, Wakada M et al (2006) 15-Deoxy-Delta 12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol Cancer Ther 5(7):1827\u20131835. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0023","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"5085_CR87","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1006\/bbrc.1999.1049","volume":"261","author":"A Sugimura","year":"1999","unstructured":"Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y et al (1999) Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1\/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 261(3):833\u2013837. https:\/\/doi.org\/10.1006\/bbrc.1999.1049","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"5085_CR88","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/sj.leu.2403328","volume":"18","author":"S Inoue","year":"2004","unstructured":"Inoue S, Snowden RT, Dyer MJ, Cohen GM (2004) CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia 18(5):948\u2013952. https:\/\/doi.org\/10.1038\/sj.leu.2403328","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"5085_CR89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000055271","volume":"57","author":"N Hirase","year":"1999","unstructured":"Hirase N, Yanase T, Mu Y, Muta K, Umemura T, Takayanagi R et al (1999) Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 57(Suppl 2):17\u201326. https:\/\/doi.org\/10.1159\/000055271","journal-title":"Oncology"},{"issue":"10","key":"5085_CR90","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1158\/1535-7163.1249.3.10","volume":"3","author":"M Konopleva","year":"2004","unstructured":"Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W et al (2004) Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3(10):1249\u20131262","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"5085_CR91","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3892\/ijo.15.5.1027","volume":"15","author":"H Asou","year":"1999","unstructured":"Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N et al (1999) Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol 15(5):1027\u20131031. https:\/\/doi.org\/10.3892\/ijo.15.5.1027","journal-title":"Int J Oncol"},{"issue":"1","key":"5085_CR92","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1182\/blood.v99.1.326","volume":"99","author":"M Konopleva","year":"2002","unstructured":"Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE et al (2002) Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99(1):326\u2013335. https:\/\/doi.org\/10.1182\/blood.v99.1.326","journal-title":"Blood"},{"issue":"5","key":"5085_CR93","first-page":"261","volume":"11","author":"Y Ito","year":"2000","unstructured":"Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda T et al (2000) The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 11(5):261\u2013267","journal-title":"Cell Growth Differ"},{"issue":"8","key":"5085_CR94","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2002-04-1174","volume":"100","author":"IM Pedersen","year":"2002","unstructured":"Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L et al (2002) The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 100(8):2965\u20132972. https:\/\/doi.org\/10.1182\/blood-2002-04-1174","journal-title":"Blood"},{"issue":"2","key":"5085_CR95","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.0022-202X.2004.23207.x","volume":"123","author":"C Zhang","year":"2004","unstructured":"Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M (2004) The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides\/Sezary syndrome cells. J Invest Dermatol 123(2):380\u2013387. https:\/\/doi.org\/10.1111\/j.0022-202X.2004.23207.x","journal-title":"J Invest Dermatol"},{"issue":"1","key":"5085_CR96","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.0019-2805.2001.01340.x","volume":"105","author":"SG Harris","year":"2002","unstructured":"Harris SG, Phipps RP (2002) Prostaglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology 105(1):23\u201334. https:\/\/doi.org\/10.1046\/j.0019-2805.2001.01340.x","journal-title":"Immunology"},{"issue":"10","key":"5085_CR97","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1182\/blood-2006-11-058941","volume":"110","author":"S Koschmieder","year":"2007","unstructured":"Koschmieder S, D\u2019Alo F, Radomska H, Schoneich C, Chang JS, Konopleva M et al (2007) CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 110(10):3695\u20133705. https:\/\/doi.org\/10.1182\/blood-2006-11-058941","journal-title":"Blood"},{"issue":"17","key":"5085_CR98","first-page":"5551","volume":"63","author":"T Ikeda","year":"2003","unstructured":"Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D (2003) The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 63(17):5551\u20135558","journal-title":"Cancer Res"},{"issue":"1","key":"5085_CR99","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000092345","volume":"116","author":"M Takenokuchi","year":"2006","unstructured":"Takenokuchi M, Saigo K, Nakamachi Y, Kawano S, Hashimoto M, Fujioka T et al (2006) Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). Acta Haematol 116(1):30\u201340. https:\/\/doi.org\/10.1159\/000092345","journal-title":"Acta Haematol"},{"issue":"21","key":"5085_CR100","doi-asserted-by":"publisher","first-page":"7927","DOI":"10.1158\/0008-5472.CAN-03-2402","volume":"64","author":"M Konopleva","year":"2004","unstructured":"Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE et al (2004) The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64(21):7927\u20137935. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-2402","journal-title":"Cancer Res"},{"issue":"5","key":"5085_CR101","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s0145-2126(99)00200-3","volume":"24","author":"N Hirase","year":"2000","unstructured":"Hirase N, Yanase T, Mu Y, Muta K, Umemura T, Takayanagi R et al (2000) Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leuk Res 24(5):393\u2013400. https:\/\/doi.org\/10.1016\/s0145-2126(99)00200-3","journal-title":"Leuk Res"},{"issue":"19","key":"5085_CR102","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4161\/cc.5.19.3259","volume":"5","author":"C Zang","year":"2006","unstructured":"Zang C, Liu H, Waechter M, Eucker J, Bertz J, Possinger K et al (2006) Dual PPARalpha\/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle 5(19):2237\u20132243. https:\/\/doi.org\/10.4161\/cc.5.19.3259","journal-title":"Cell Cycle"},{"issue":"12","key":"5085_CR103","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.4161\/cbt.6.12.4982","volume":"6","author":"Y Tabe","year":"2007","unstructured":"Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S et al (2007) PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther 6(12):1967\u20131977. https:\/\/doi.org\/10.4161\/cbt.6.12.4982","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"5085_CR104","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/s0014-2999(00)00461-1","volume":"401","author":"U Kintscher","year":"2000","unstructured":"Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA et al (2000) Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 401(3):259\u2013270. https:\/\/doi.org\/10.1016\/s0014-2999(00)00461-1","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"5085_CR105","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1006\/bbrc.1998.9567","volume":"251","author":"L Zhu","year":"1998","unstructured":"Zhu L, Gong B, Bisgaier CL, Aviram M, Newton RS (1998) Induction of PPARgamma1 expression in human THP-1 monocytic leukemia cells by 9-cis-retinoic acid is associated with cellular growth suppression. Biochem Biophys Res Commun 251(3):842\u2013848. https:\/\/doi.org\/10.1006\/bbrc.1998.9567","journal-title":"Biochem Biophys Res Commun"},{"issue":"7569","key":"5085_CR106","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G et al (2015) Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 525(7569):380\u2013383. https:\/\/doi.org\/10.1038\/nature15248","journal-title":"Nature"},{"issue":"11","key":"5085_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02849","volume":"5","author":"C Koshiishi","year":"2019","unstructured":"Koshiishi C, Kanazawa T, Vangrevelinghe E, Honda T, Hatakeyama S (2019) Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR\/RXR agonist. Heliyon 5(11):e02849. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02849","journal-title":"Heliyon"},{"issue":"24","key":"5085_CR108","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1093\/emboj\/18.24.7011","volume":"18","author":"G Benoit","year":"1999","unstructured":"Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raffelsberger W et al (1999) RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J 18(24):7011\u20137018. https:\/\/doi.org\/10.1093\/emboj\/18.24.7011","journal-title":"EMBO J"},{"issue":"6","key":"5085_CR109","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M et al (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian\u2013German APL0406 trial. J Clin Oncol 35(6):605\u2013612. https:\/\/doi.org\/10.1200\/JCO.2016.67.1982","journal-title":"J Clin Oncol"},{"issue":"2","key":"5085_CR110","first-page":"179","volume":"7","author":"K Mehta","year":"1996","unstructured":"Mehta K, McQueen T, Neamati N, Collins S, Andreeff M (1996) Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 7(2):179\u2013186","journal-title":"Cell Growth Differ"},{"issue":"8","key":"5085_CR111","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","volume":"120","author":"HJ Iland","year":"2012","unstructured":"Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M et al (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120(8):1570\u20131580. https:\/\/doi.org\/10.1182\/blood-2012-02-410746","journal-title":"Blood"},{"issue":"2","key":"5085_CR112","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"issue":"1","key":"5085_CR113","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/ol.2014.2133","volume":"8","author":"L Xiang","year":"2014","unstructured":"Xiang L, Dong W, Wang R, Wei J, Qiu G, Cen J et al (2014) All-trans retinoic acid enhances the effect of 5-aza-2\u2019-deoxycytidine on p16INK4a demethylation, and the two drugs synergistically activate retinoic acid receptor beta gene expression in the human erythroleukemia K562 cell line. Oncol Lett 8(1):117\u2013122. https:\/\/doi.org\/10.3892\/ol.2014.2133","journal-title":"Oncol Lett"},{"issue":"15","key":"5085_CR114","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1073\/pnas.0400053101","volume":"101","author":"ZX Shen","year":"2004","unstructured":"Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM et al (2004) All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101(15):5328\u20135335. https:\/\/doi.org\/10.1073\/pnas.0400053101","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"5085_CR115","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-07-5185","volume":"14","author":"DE Tsai","year":"2008","unstructured":"Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M et al (2008) A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res 14(17):5619\u20135625. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5185","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5085_CR116","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1078\/0171-9335-00141","volume":"80","author":"TE Battle","year":"2001","unstructured":"Battle TE, Roberson MS, Zhang T, Varvayanis S, Yen A (2001) Retinoic acid-induced blr1 expression requires RARalpha, RXR, and MAPK activation and uses ERK2 but not JNK\/SAPK to accelerate cell differentiation. Eur J Cell Biol 80(1):59\u201367. https:\/\/doi.org\/10.1078\/0171-9335-00141","journal-title":"Eur J Cell Biol"},{"issue":"2","key":"5085_CR117","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood.V84.2.446.446","volume":"84","author":"MI Dawson","year":"1994","unstructured":"Dawson MI, Elstner E, Kizaki M, Chen DL, Pakkala S, Kerner B et al (1994) Myeloid differentiation mediated through retinoic acid receptor\/retinoic X receptor (RXR) not RXR\/RXR pathway. Blood 84(2):446\u2013452","journal-title":"Blood"},{"issue":"5","key":"5085_CR118","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1182\/blood.V87.5.1977.1977","volume":"87","author":"M Kizaki","year":"1996","unstructured":"Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S et al (1996) Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 87(5):1977\u20131984","journal-title":"Blood"},{"issue":"12","key":"5085_CR119","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1182\/blood.V82.12.3592.3592","volume":"82","author":"M Kizaki","year":"1993","unstructured":"Kizaki M, Ikeda Y, Tanosaki R, Nakajima H, Morikawa M, Sakashita A et al (1993) Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells. Blood 82(12):3592\u20133599","journal-title":"Blood"},{"issue":"1","key":"5085_CR120","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0167-4889(97)00099-2","volume":"1359","author":"Y Kanatani","year":"1997","unstructured":"Kanatani Y, Makishima M, Asahi K, Sakurai A, Takahashi N, Motoyoshi K et al (1997) Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid. Biochim Biophys Acta 1359(1):71\u201379. https:\/\/doi.org\/10.1016\/s0167-4889(97)00099-2","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"5085_CR121","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.V81.4.1009.1009","volume":"81","author":"A Sakashita","year":"1993","unstructured":"Sakashita A, Kizaki M, Pakkala S, Schiller G, Tsuruoka N, Tomosaki R et al (1993) 9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro. Blood 81(4):1009\u20131016","journal-title":"Blood"},{"issue":"11","key":"5085_CR122","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood.V85.11.3021.bloodjournal85113021","volume":"85","author":"WH Miller Jr","year":"1995","unstructured":"Miller WH Jr, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F et al (1995) 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85(11):3021\u20133027","journal-title":"Blood"},{"issue":"2","key":"5085_CR123","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/excr.1997.3620","volume":"234","author":"SC Brooks 3rd","year":"1997","unstructured":"Brooks SC 3rd, Sturgill R, Choi J, Yen A (1997) An RXR-selective analog attenuates the RAR alpha-selective analog-induced differentiation and non-G1-restricted growth arrest of NB4 cells. Exp Cell Res 234(2):259\u2013269. https:\/\/doi.org\/10.1006\/excr.1997.3620","journal-title":"Exp Cell Res"},{"key":"5085_CR124","doi-asserted-by":"publisher","first-page":"5971080","DOI":"10.1155\/2018\/5971080","volume":"2018","author":"HT Vu","year":"2018","unstructured":"Vu HT, Hoang TX, Kim JY (2018) All-trans retinoic acid enhances matrix metalloproteinase 2 Expression and secretion in human myeloid leukemia THP-1 cells. Biomed Res Int 2018:5971080. https:\/\/doi.org\/10.1155\/2018\/5971080","journal-title":"Biomed Res Int"},{"issue":"6","key":"5085_CR125","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1182\/blood.V93.6.2057.406k04_2057_2066","volume":"93","author":"M Shiohara","year":"1999","unstructured":"Shiohara M, Dawson MI, Hobbs PD, Sawai N, Higuchi T, Koike K et al (1999) Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. Blood 93(6):2057\u20132066","journal-title":"Blood"},{"issue":"6","key":"5085_CR126","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3858\/emm.2009.41.6.048","volume":"41","author":"K Kim","year":"2009","unstructured":"Kim K, Choi YH, Kim HH, Cheong J (2009) The orphan nuclear receptor SHP inhibits apoptosis during the monocytic differentiation by inducing p21WAF1. Exp Mol Med 41(6):429\u2013439. https:\/\/doi.org\/10.3858\/emm.2009.41.6.048","journal-title":"Exp Mol Med"},{"issue":"11","key":"5085_CR127","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1021\/jm200051z","volume":"54","author":"Z Xia","year":"2011","unstructured":"Xia Z, Farhana L, Correa RG, Das JK, Castro DJ, Yu J et al (2011) Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid. J Med Chem 54(11):3793\u20133816. https:\/\/doi.org\/10.1021\/jm200051z","journal-title":"J Med Chem"},{"issue":"1","key":"5085_CR128","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1021\/jm2011436","volume":"55","author":"Z Xia","year":"2012","unstructured":"Xia Z, Correa RG, Das JK, Farhana L, Castro DJ, Yu J et al (2012) Analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid. 2. Impact of 3-chloro group replacement on inhibition of proliferation and induction of apoptosis of leukemia and cancer cell lines. J Med Chem 55(1):233\u2013249. https:\/\/doi.org\/10.1021\/jm2011436","journal-title":"J Med Chem"},{"issue":"3","key":"5085_CR129","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4161\/cbt.11.3.14098","volume":"11","author":"I Bobilev","year":"2011","unstructured":"Bobilev I, Novik V, Levi I, Shpilberg O, Levy J, Sharoni Y et al (2011) The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells. Cancer Biol Ther 11(3):317\u2013329. https:\/\/doi.org\/10.4161\/cbt.11.3.14098","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"5085_CR130","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/cancers14020387","volume":"14","author":"JJ Gleba","year":"2022","unstructured":"Gleba JJ, Klopotowska D, Banach J, Turlej E, Mielko KA, Gebura K et al (2022) Polymorphism of VDR gene and the sensitivity of human leukemia and lymphoma cells to active forms of vitamin D. Cancers (Basel) 14(2):387. https:\/\/doi.org\/10.3390\/cancers14020387","journal-title":"Cancers (Basel)"},{"issue":"2","key":"5085_CR131","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.clnu.2016.01.021","volume":"36","author":"A Radujkovic","year":"2017","unstructured":"Radujkovic A, Schnitzler P, Ho AD, Dreger P, Luft T (2017) Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia. Clin Nutr 36(2):542\u2013551. https:\/\/doi.org\/10.1016\/j.clnu.2016.01.021","journal-title":"Clin Nutr"},{"key":"5085_CR132","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jsbmb.2018.11.017","volume":"188","author":"M Nachliely","year":"2019","unstructured":"Nachliely M, Trachtenberg A, Khalfin B, Nalbandyan K, Cohen-Lahav M, Yasuda K et al (2019) Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model. J Steroid Biochem Mol Biol 188:8\u201316. https:\/\/doi.org\/10.1016\/j.jsbmb.2018.11.017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"5085_CR133","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-15-2290","volume":"76","author":"K Gupta","year":"2016","unstructured":"Gupta K, Stefan T, Ignatz-Hoover J, Moreton S, Parizher G, Saunthararajah Y et al (2016) GSK-3 inhibition sensitizes acute myeloid leukemia cells to 1,25D-mediated differentiation. Cancer Res 76(9):2743\u20132753. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2290","journal-title":"Cancer Res"},{"issue":"34\u201338","key":"5085_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2017.01.001","volume":"49","author":"EA Mostaghel","year":"2017","unstructured":"Mostaghel EA, Martin PS, Mongovin S, Frayo S, Zhang A, Edlefsen KL et al (2017) Androgen receptor expression in mantle cell lymphoma: potential novel therapeutic implications. Exp Hematol 49(34\u201338):e32. https:\/\/doi.org\/10.1016\/j.exphem.2017.01.001","journal-title":"Exp Hematol"},{"issue":"7","key":"5085_CR135","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/leu.2011.68","volume":"25","author":"K Yakimchuk","year":"2011","unstructured":"Yakimchuk K, Iravani M, Hasni MS, Rhonnstad P, Nilsson S, Jondal M et al (2011) Effect of ligand-activated estrogen receptor beta on lymphoma growth in vitro and in vivo. Leukemia 25(7):1103\u20131110. https:\/\/doi.org\/10.1038\/leu.2011.68","journal-title":"Leukemia"},{"issue":"13","key":"5085_CR136","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1182\/blood-2013-07-517292","volume":"123","author":"K Yakimchuk","year":"2014","unstructured":"Yakimchuk K, Hasni MS, Guan J, Chao MP, Sander B, Okret S (2014) Inhibition of lymphoma vascularization and dissemination by estrogen receptor beta agonists. Blood 123(13):2054\u20132061. https:\/\/doi.org\/10.1182\/blood-2013-07-517292","journal-title":"Blood"},{"issue":"12","key":"5085_CR137","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1530\/EC-18-0459","volume":"7","author":"K Yakimchuk","year":"2018","unstructured":"Yakimchuk K, Bangalore Revanna C, Huang D, Inzunza J, Okret S (2018) Suppression of lymphoma growth by the xenoestrogens bisphenol A and genistein. Endocr Connect 7(12):1472\u20131479. https:\/\/doi.org\/10.1530\/EC-18-0459","journal-title":"Endocr Connect"},{"issue":"5","key":"5085_CR138","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1182\/blood.V84.5.1613.1613","volume":"84","author":"LA Smets","year":"1994","unstructured":"Smets LA, Van den Berg J, Acton D, Top B, Van Rooij H, Verwijs-Janssen M (1994) BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 84(5):1613\u20131619","journal-title":"Blood"},{"issue":"23","key":"5085_CR139","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1182\/blood-2016-06-724807","volume":"128","author":"A Ceroi","year":"2016","unstructured":"Ceroi A, Masson D, Roggy A, Roumier C, Chague C, Gauthier T et al (2016) LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. Blood 128(23):2694\u20132707. https:\/\/doi.org\/10.1182\/blood-2016-06-724807","journal-title":"Blood"},{"issue":"15","key":"5085_CR140","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2013-08-518878","volume":"123","author":"AJ Deutsch","year":"2014","unstructured":"Deutsch AJ, Rinner B, Wenzl K, Pichler M, Troppan K, Steinbauer E et al (2014) NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas. Blood 123(15):2367\u20132377. https:\/\/doi.org\/10.1182\/blood-2013-08-518878","journal-title":"Blood"},{"issue":"17","key":"5085_CR141","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1182\/blood-2008-08-176024","volume":"113","author":"J Chen","year":"2009","unstructured":"Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R et al (2009) Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 113(17):4038\u20134048. https:\/\/doi.org\/10.1182\/blood-2008-08-176024","journal-title":"Blood"},{"issue":"1","key":"5085_CR142","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1006\/clim.2001.5181","volume":"103","author":"J Padilla","year":"2002","unstructured":"Padilla J, Leung E, Phipps RP (2002) Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists. Clin Immunol 103(1):22\u201333. https:\/\/doi.org\/10.1006\/clim.2001.5181","journal-title":"Clin Immunol"},{"issue":"5","key":"5085_CR143","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/CAD.0b013e3280200414","volume":"18","author":"JD Burton","year":"2007","unstructured":"Burton JD, Castillo ME, Goldenberg DM, Blumenthal RD (2007) Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines. Anticancer Drugs 18(5):525\u2013534. https:\/\/doi.org\/10.1097\/CAD.0b013e3280200414","journal-title":"Anticancer Drugs"},{"issue":"11","key":"5085_CR144","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/exd.13348","volume":"26","author":"L Wang","year":"2017","unstructured":"Wang L, DeMarco SS, Peaks MS, Maiorana-Boutilier AL, Chen J, Crouch MJ et al (2017) RARalpha\/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines. Exp Dermatol 26(11):1004\u20131011. https:\/\/doi.org\/10.1111\/exd.13348","journal-title":"Exp Dermatol"},{"issue":"1\u20133","key":"5085_CR145","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jsbmb.2008.08.001","volume":"112","author":"S Qin","year":"2008","unstructured":"Qin S, Okawa Y, Atangan LI, Brown G, Chandraratna RA, Zhao Y (2008) Integrities of A\/B and C domains of RXR are required for rexinoid-induced caspase activations and apoptosis. J Steroid Biochem Mol Biol 112(1\u20133):25\u201331. https:\/\/doi.org\/10.1016\/j.jsbmb.2008.08.001","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"8","key":"5085_CR146","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/jid.2015.122","volume":"135","author":"L Wang","year":"2015","unstructured":"Wang L, DeMarco SS, Chen J, Phillips CM, Bridges LC (2015) Retinoids bias integrin expression and function in cutaneous T-Cell lymphoma. J Invest Dermatol 135(8):2102\u20132108. https:\/\/doi.org\/10.1038\/jid.2015.122","journal-title":"J Invest Dermatol"},{"issue":"3","key":"5085_CR147","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2174\/1871520617666170327115657","volume":"18","author":"H Yang","year":"2018","unstructured":"Yang H, Ma P, Cao Y, Zhang M, Li L, Wei J et al (2018) ECPIRM, a potential therapeutic agent for cutaneous T-cell lymphoma, inhibits cell proliferation and promotes apoptosis via a JAK\/STAT pathway. Anticancer Agents Med Chem 18(3):401\u2013411. https:\/\/doi.org\/10.2174\/1871520617666170327115657","journal-title":"Anticancer Agents Med Chem"},{"issue":"3","key":"5085_CR148","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jdermsci.2018.03.006","volume":"90","author":"CF Chou","year":"2018","unstructured":"Chou CF, Hsieh YH, Grubbs CJ, Atigadda VR, Mobley JA, Dummer R et al (2018) The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci 90(3):343\u2013356. https:\/\/doi.org\/10.1016\/j.jdermsci.2018.03.006","journal-title":"J Dermatol Sci"},{"issue":"5","key":"5085_CR149","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1067\/mjd.2002.124607","volume":"47","author":"R Talpur","year":"2002","unstructured":"Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M (2002) Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 47(5):672\u2013684. https:\/\/doi.org\/10.1067\/mjd.2002.124607","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"5085_CR150","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","volume":"53","author":"R Dummer","year":"2012","unstructured":"Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M et al (2012) Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma 53(8):1501\u20131508. https:\/\/doi.org\/10.3109\/10428194.2012.656625","journal-title":"Leuk Lymphoma"},{"issue":"29","key":"5085_CR151","doi-asserted-by":"publisher","first-page":"30844","DOI":"10.1074\/jbc.M404651200","volume":"279","author":"Y Zhao","year":"2004","unstructured":"Zhao Y, Qin S, Atangan LI, Molina Y, Okawa Y, Arpawong HT et al (2004) Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis. J Biol Chem 279(29):30844\u201330849. https:\/\/doi.org\/10.1074\/jbc.M404651200","journal-title":"J Biol Chem"},{"issue":"2","key":"5085_CR152","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","volume":"106","author":"F Foss","year":"2005","unstructured":"Foss F, Demierre MF, DiVenuti G (2005) A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106(2):454\u2013457. https:\/\/doi.org\/10.1182\/blood-2004-11-4570","journal-title":"Blood"},{"issue":"9","key":"5085_CR153","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P et al (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19(9):2456\u20132471. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2456","journal-title":"J Clin Oncol"},{"issue":"1","key":"5085_CR154","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13104-019-4241-0","volume":"12","author":"R Gharbaran","year":"2019","unstructured":"Gharbaran R, Zhang B, Valerio L, Onwumere O, Wong M, Mighty J et al (2019) Effects of vitamin D3 and its chemical analogs on the growth of Hodgkin\u2019s lymphoma, in vitro. BMC Res Notes 12(1):216. https:\/\/doi.org\/10.1186\/s13104-019-4241-0","journal-title":"BMC Res Notes"},{"key":"5085_CR155","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1196\/annals.1299.057","volume":"1010","author":"J Gauduchon","year":"2003","unstructured":"Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir MJ, Sola B (2003) The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines. Ann N Y Acad Sci 1010:321\u2013325. https:\/\/doi.org\/10.1196\/annals.1299.057","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"5085_CR156","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1600-0609.1987.tb00164.x","volume":"39","author":"T Murakami","year":"1987","unstructured":"Murakami T, Togawa A, Satch H, Katoh M, Imamura Y, Ohsawa N et al (1987) Glucocorticoid receptor in multiple myeloma. Eur J Haematol 39(1):54\u201359. https:\/\/doi.org\/10.1111\/j.1600-0609.1987.tb00164.x","journal-title":"Eur J Haematol"},{"issue":"1","key":"5085_CR157","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12885-020-06735-2","volume":"20","author":"P Sriskandarajah","year":"2020","unstructured":"Sriskandarajah P, De Haven Brandon A, MacLeod K, Carragher NO, Kirkin V, Kaiser M et al (2020) Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. BMC Cancer 20(1):269. https:\/\/doi.org\/10.1186\/s12885-020-06735-2","journal-title":"BMC Cancer"},{"issue":"5","key":"5085_CR158","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/10428190902801838","volume":"50","author":"M Yang","year":"2009","unstructured":"Yang M, Shen JK, Huang J, Du HP, Ma QL, Jin J (2009) Interleukin-6-independent expression of glucocorticoid receptor is upregulated by triptolide in multiple myeloma. Leuk Lymphoma 50(5):802\u2013808. https:\/\/doi.org\/10.1080\/10428190902801838","journal-title":"Leuk Lymphoma"},{"key":"5085_CR159","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fphar.2015.00230","volume":"6","author":"H Dong","year":"2015","unstructured":"Dong H, Carlton ME, Lerner A, Epstein PM (2015) Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol 6:230. https:\/\/doi.org\/10.3389\/fphar.2015.00230","journal-title":"Front Pharmacol"},{"issue":"19","key":"5085_CR160","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1021\/jm070370z","volume":"50","author":"AR Hudson","year":"2007","unstructured":"Hudson AR, Roach SL, Higuchi RI, Phillips DP, Bissonnette RP, Lamph WW et al (2007) Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma. J Med Chem 50(19):4699\u20134709. https:\/\/doi.org\/10.1021\/jm070370z","journal-title":"J Med Chem"},{"issue":"3","key":"5085_CR161","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12672-011-0072-8","volume":"2","author":"MA Tessel","year":"2011","unstructured":"Tessel MA, Benham AL, Krett NL, Rosen ST, Gunaratne PH (2011) Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer 2(3):182\u2013189. https:\/\/doi.org\/10.1007\/s12672-011-0072-8","journal-title":"Horm Cancer"},{"issue":"6","key":"5085_CR162","first-page":"1873","volume":"50","author":"M Gomi","year":"1990","unstructured":"Gomi M, Moriwaki K, Katagiri S, Kurata Y, Thompson EB (1990) Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res 50(6):1873\u20131878","journal-title":"Cancer Res"},{"issue":"12","key":"5085_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113842","volume":"9","author":"A Palagani","year":"2014","unstructured":"Palagani A, Op de Beeck K, Naulaerts S, Diddens J, Sekhar Chirumamilla C, Van Camp G et al (2014) Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells. PLoS ONE 9(12):e113842. https:\/\/doi.org\/10.1371\/journal.pone.0113842","journal-title":"PLoS ONE"},{"issue":"5","key":"5085_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197000","volume":"13","author":"D Clarisse","year":"2018","unstructured":"Clarisse D, Van Wesemael K, Tavernier J, Offner F, Beck IM, De Bosscher K (2018) Effect of combining glucocorticoids with compound A on glucocorticoid receptor responsiveness in lymphoid malignancies. PLoS ONE 13(5):e0197000. https:\/\/doi.org\/10.1371\/journal.pone.0197000","journal-title":"PLoS ONE"},{"issue":"2","key":"5085_CR165","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00874441","volume":"12","author":"V Gupta","year":"1994","unstructured":"Gupta V, Thompson EB, Stock-Novack D, Salmon SE, Pierce HI, Bonnet JD et al (1994) Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors. A southwest oncology group study. Invest New Drugs 12(2):121\u2013128. https:\/\/doi.org\/10.1007\/BF00874441","journal-title":"Invest New Drugs"},{"issue":"4","key":"5085_CR166","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1182\/blood-2007-11-124156","volume":"112","author":"S Sharma","year":"2008","unstructured":"Sharma S, Lichtenstein A (2008) Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 112(4):1338\u20131345. https:\/\/doi.org\/10.1182\/blood-2007-11-124156","journal-title":"Blood"},{"issue":"20","key":"5085_CR167","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-08-0457","volume":"14","author":"TM Garcia-Bates","year":"2008","unstructured":"Garcia-Bates TM, Bernstein SH, Phipps RP (2008) Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clin Cancer Res 14(20):6414\u20136425. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0457","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5085_CR168","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clim.2004.06.011","volume":"113","author":"DM Ray","year":"2004","unstructured":"Ray DM, Bernstein SH, Phipps RP (2004) Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 113(2):203\u2013213. https:\/\/doi.org\/10.1016\/j.clim.2004.06.011","journal-title":"Clin Immunol"},{"issue":"4","key":"5085_CR169","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/blood-2004-04-1360","volume":"105","author":"R Piva","year":"2005","unstructured":"Piva R, Gianferretti P, Ciucci A, Taulli R, Belardo G, Santoro MG (2005) 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood 105(4):1750\u20131758. https:\/\/doi.org\/10.1182\/blood-2004-04-1360","journal-title":"Blood"},{"issue":"10","key":"5085_CR170","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/00001813-200411000-00004","volume":"15","author":"J Eucker","year":"2004","unstructured":"Eucker J, Bangeroth K, Zavrski I, Krebbel H, Zang C, Heider U et al (2004) Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. Anticancer Drugs 15(10):955\u2013960. https:\/\/doi.org\/10.1097\/00001813-200411000-00004","journal-title":"Anticancer Drugs"},{"issue":"7","key":"5085_CR171","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.V91.7.2423","volume":"91","author":"B Joseph","year":"1998","unstructured":"Joseph B, Lefebvre O, Mereau-Richard C, Danze PM, Belin-Plancot MT, Formstecher P (1998) Evidence for the involvement of both retinoic acid receptor- and retinoic X receptor-dependent signaling pathways in the induction of tissue transglutaminase and apoptosis in the human myeloma cell line RPMI 8226. Blood 91(7):2423\u20132432","journal-title":"Blood"},{"issue":"19","key":"5085_CR172","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ et al (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19):4375\u20134382. https:\/\/doi.org\/10.1182\/blood-2011-11-395749","journal-title":"Blood"},{"issue":"2\u20133","key":"5085_CR173","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","volume":"33","author":"Z Culig","year":"2014","unstructured":"Culig Z, Santer FR (2014) Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev 33(2\u20133):413\u2013427. https:\/\/doi.org\/10.1007\/s10555-013-9474-0","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"5085_CR174","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1124\/pr.112.006833","volume":"65","author":"TP Burris","year":"2013","unstructured":"Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K et al (2013) Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 65(2):710\u2013778. https:\/\/doi.org\/10.1124\/pr.112.006833","journal-title":"Pharmacol Rev"},{"issue":"D1","key":"5085_CR175","doi-asserted-by":"publisher","first-page":"D1003","DOI":"10.1093\/nar\/gkac888","volume":"51","author":"RL Seal","year":"2023","unstructured":"Seal RL, Braschi B, Gray K, Jones TEM, Tweedie S, Haim-Vilmovsky L et al (2023) Genenames.org: the HGNC resources in 2023. Nucleic Acids Res 51(D1):D1003\u2013D1009. https:\/\/doi.org\/10.1093\/nar\/gkac888","journal-title":"Nucleic Acids Res"},{"issue":"6220","key":"5085_CR176","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A et al (2015) Proteomics. Tissue-based map of the human proteome. Science 347(6220):1260419. https:\/\/doi.org\/10.1126\/science.1260419","journal-title":"Science"},{"issue":"1","key":"5085_CR177","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1677\/ERC-08-0150","volume":"16","author":"J Yang","year":"2009","unstructured":"Yang J, Zhao YL, Wu ZQ, Si YL, Meng YG, Fu XB et al (2009) The single-macro domain protein LRP16 is an essential cofactor of androgen receptor. Endocr Relat Cancer 16(1):139\u2013153. https:\/\/doi.org\/10.1677\/ERC-08-0150","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"5085_CR178","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan MH, Li J, Xu HE, Melcher K, Yong EL (2015) Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 36(1):3\u201323. https:\/\/doi.org\/10.1038\/aps.2014.18","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"5085_CR179","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/med.21558","volume":"39","author":"D Li","year":"2019","unstructured":"Li D, Zhou W, Pang J, Tang Q, Zhong B, Shen C et al (2019) A magic drug target: androgen receptor. Med Res Rev 39(5):1485\u20131514. https:\/\/doi.org\/10.1002\/med.21558","journal-title":"Med Res Rev"},{"issue":"4","key":"5085_CR180","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.beem.2015.04.008","volume":"29","author":"M Jia","year":"2015","unstructured":"Jia M, Dahlman-Wright K, Gustafsson JA (2015) Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab 29(4):557\u2013568. https:\/\/doi.org\/10.1016\/j.beem.2015.04.008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"5085_CR181","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1080\/07391102.2022.2027818","volume":"41","author":"A Fischer","year":"2023","unstructured":"Fischer A, Bardakci F, Sellner M, Lill MA, Smiesko M (2023) Ligand pathways in estrogen-related receptors. J Biomol Struct Dyn 41(5):1639\u20131648. https:\/\/doi.org\/10.1080\/07391102.2022.2027818","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"5085_CR182","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1677\/jme.0.0310349","volume":"31","author":"B Horard","year":"2003","unstructured":"Horard B, Vanacker JM (2003) Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endocrinol 31(3):349\u2013357. https:\/\/doi.org\/10.1677\/jme.0.0310349","journal-title":"J Mol Endocrinol"},{"issue":"5","key":"5085_CR183","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1042\/BST20210419","volume":"49","author":"F Frank","year":"2021","unstructured":"Frank F, Ortlund EA, Liu X (2021) Structural insights into glucocorticoid receptor function. Biochem Soc Trans 49(5):2333\u20132343. https:\/\/doi.org\/10.1042\/BST20210419","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"5085_CR184","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1074\/jbc.R110.179325","volume":"286","author":"RH Oakley","year":"2011","unstructured":"Oakley RH, Cidlowski JA (2011) Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 286(5):3177\u20133184. https:\/\/doi.org\/10.1074\/jbc.R110.179325","journal-title":"J Biol Chem"},{"issue":"3","key":"5085_CR185","doi-asserted-by":"publisher","first-page":"647","DOI":"10.20517\/cdr.2019.29","volume":"2","author":"B Scheijen","year":"2019","unstructured":"Scheijen B (2019) Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies. Cancer Drug Resist 2(3):647\u2013664. https:\/\/doi.org\/10.20517\/cdr.2019.29","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"5085_CR186","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1172\/JCI117943","volume":"95","author":"CM Bamberger","year":"1995","unstructured":"Bamberger CM, Bamberger AM, de Castro M, Chrousos GP (1995) Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95(6):2435\u20132441. https:\/\/doi.org\/10.1172\/JCI117943","journal-title":"J Clin Invest"},{"issue":"39","key":"5085_CR187","doi-asserted-by":"publisher","first-page":"27857","DOI":"10.1074\/jbc.274.39.27857","volume":"274","author":"RH Oakley","year":"1999","unstructured":"Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA (1999) The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 274(39):27857\u201327866. https:\/\/doi.org\/10.1074\/jbc.274.39.27857","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"5085_CR188","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0303-7207(99)00072-6","volume":"153","author":"P de Lange","year":"1999","unstructured":"de Lange P, Koper JW, Brinkmann AO, de Jong FH, Lamberts SW (1999) Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids. Mol Cell Endocrinol 153(1\u20132):163\u2013168. https:\/\/doi.org\/10.1016\/s0303-7207(99)00072-6","journal-title":"Mol Cell Endocrinol"},{"issue":"1\u20132","key":"5085_CR189","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s0303-7207(99)00156-2","volume":"157","author":"IJ Brogan","year":"1999","unstructured":"Brogan IJ, Murray IA, Cerillo G, Needham M, White A, Davis JR (1999) Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-kappaB: lack of effect of glucocorticoid receptor beta. Mol Cell Endocrinol 157(1\u20132):95\u2013104. https:\/\/doi.org\/10.1016\/s0303-7207(99)00156-2","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"5085_CR190","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.bbrc.2009.02.110","volume":"381","author":"T Kino","year":"2009","unstructured":"Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP (2009) Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem Biophys Res Commun 381(4):671\u2013675. https:\/\/doi.org\/10.1016\/j.bbrc.2009.02.110","journal-title":"Biochem Biophys Res Commun"},{"issue":"42","key":"5085_CR191","doi-asserted-by":"publisher","first-page":"26659","DOI":"10.1074\/jbc.272.42.26659","volume":"272","author":"K Hecht","year":"1997","unstructured":"Hecht K, Carlstedt-Duke J, Stierna P, Gustafsson J, Bronnegard M, Wikstrom AC (1997) Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor. J Biol Chem 272(42):26659\u201326664. https:\/\/doi.org\/10.1074\/jbc.272.42.26659","journal-title":"J Biol Chem"},{"issue":"3","key":"5085_CR192","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1006\/bbrc.1998.9980","volume":"254","author":"H Shahidi","year":"1999","unstructured":"Shahidi H, Vottero A, Stratakis CA, Taymans SE, Karl M, Longui CA et al (1999) Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem Biophys Res Commun 254(3):559\u2013565. https:\/\/doi.org\/10.1006\/bbrc.1998.9980","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"5085_CR193","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/pbc.20308","volume":"45","author":"Y Koga","year":"2005","unstructured":"Koga Y, Matsuzaki A, Suminoe A, Hattori H, Kanemitsu S, Hara T (2005) Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 45(2):121\u2013127. https:\/\/doi.org\/10.1002\/pbc.20308","journal-title":"Pediatr Blood Cancer"},{"issue":"6680","key":"5085_CR194","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/30032","volume":"393","author":"CJ Fryer","year":"1998","unstructured":"Fryer CJ, Archer TK (1998) Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature 393(6680):88\u201391. https:\/\/doi.org\/10.1038\/30032","journal-title":"Nature"},{"key":"5085_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105540","volume":"119","author":"B Elgendy","year":"2022","unstructured":"Elgendy B, Griffett K, Hegazy L, Di Fruscia P, Sample K, Schoepke E et al (2022) Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorg Chem 119:105540. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105540","journal-title":"Bioorg Chem"},{"issue":"5","key":"5085_CR196","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1189\/jlb.0509295","volume":"86","author":"KW Christopherson 2nd","year":"2009","unstructured":"Christopherson KW 2nd, Landay A (2009) Liver X receptor alpha (LXRalpha) as a therapeutic target in chronic lymphocytic leukemia (CLL). J Leukoc Biol 86(5):1019\u20131021. https:\/\/doi.org\/10.1189\/jlb.0509295","journal-title":"J Leukoc Biol"},{"issue":"11","key":"5085_CR197","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/nm1102-1243","volume":"8","author":"JJ Repa","year":"2002","unstructured":"Repa JJ, Mangelsdorf DJ (2002) The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 8(11):1243\u20131248. https:\/\/doi.org\/10.1038\/nm1102-1243","journal-title":"Nat Med"},{"issue":"4","key":"5085_CR198","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2015.03.002","volume":"21","author":"F Bovenga","year":"2015","unstructured":"Bovenga F, Sabba C, Moschetta A (2015) Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab 21(4):517\u2013526. https:\/\/doi.org\/10.1016\/j.cmet.2015.03.002","journal-title":"Cell Metab"},{"issue":"1","key":"5085_CR199","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450115666141120112818","volume":"16","author":"K Wenzl","year":"2015","unstructured":"Wenzl K, Troppan K, Neumeister P, Deutsch AJ (2015) The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms. Curr Drug Targets 16(1):38\u201346. https:\/\/doi.org\/10.2174\/1389450115666141120112818","journal-title":"Curr Drug Targets"},{"issue":"3","key":"5085_CR200","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1471-4159.2008.05432.x","volume":"106","author":"PC Lin","year":"2008","unstructured":"Lin PC, Chen YL, Chiu SC, Yu YL, Chen SP, Chien MH et al (2008) Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J Neurochem 106(3):1017\u20131026. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05432.x","journal-title":"J Neurochem"},{"issue":"6","key":"5085_CR201","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1042\/EBC20210004","volume":"65","author":"SC Lith","year":"2021","unstructured":"Lith SC, de Vries CJM (2021) Nuclear receptor Nur77: its role in chronic inflammatory diseases. Essays Biochem 65(6):927\u2013939. https:\/\/doi.org\/10.1042\/EBC20210004","journal-title":"Essays Biochem"},{"issue":"6","key":"5085_CR202","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.3892\/mmr.2018.9515","volume":"18","author":"L Wu","year":"2018","unstructured":"Wu L, Chen L (2018) Characteristics of Nur77 and its ligands as potential anticancer compounds (Review). Mol Med Rep 18(6):4793\u20134801. https:\/\/doi.org\/10.3892\/mmr.2018.9515","journal-title":"Mol Med Rep"},{"issue":"1","key":"5085_CR203","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1517\/14728222.11.1.69","volume":"11","author":"XK Zhang","year":"2007","unstructured":"Zhang XK (2007) Targeting Nur77 translocation. Expert Opin Ther Targets 11(1):69\u201379. https:\/\/doi.org\/10.1517\/14728222.11.1.69","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"5085_CR204","first-page":"589","volume":"27","author":"JP Wu","year":"2021","unstructured":"Wu JP, Zhang GY, Chen SQ, Chen M (2021) Nur77 inhibits the proliferation of prostate cancer cells. Zhonghua Nan Ke Xue 27(7):589\u2013594","journal-title":"Zhonghua Nan Ke Xue"},{"issue":"21","key":"5085_CR205","doi-asserted-by":"publisher","first-page":"8871","DOI":"10.1158\/0008-5472.CAN-08-1972","volume":"68","author":"J Liu","year":"2008","unstructured":"Liu J, Zhou W, Li SS, Sun Z, Lin B, Lang YY et al (2008) Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogues. Cancer Res 68(21):8871\u20138880. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1972","journal-title":"Cancer Res"},{"issue":"5","key":"5085_CR206","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1535-7163.MCT-18-0918","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Cao X, Tu X, Alitongbieke G, Xia Z, Li X et al (2019) BI1071, a novel nur77 modulator, induces apoptosis of cancer cells by activating the Nur77-Bcl-2 apoptotic pathway. Mol Cancer Ther 18(5):886\u2013899. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0918","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"5085_CR207","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1210\/endo.141.7.7562","volume":"141","author":"PM Fernandez","year":"2000","unstructured":"Fernandez PM, Brunel F, Jimenez MA, Saez JM, Cereghini S, Zakin MM (2000) Nuclear receptors Nor1 and NGFI-B\/Nur77 play similar, albeit distinct, roles in the hypothalamo-pituitary-adrenal axis. Endocrinology 141(7):2392\u20132400. https:\/\/doi.org\/10.1210\/endo.141.7.7562","journal-title":"Endocrinology"},{"issue":"2","key":"5085_CR208","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1158\/1541-7786.MCR-20-0707","volume":"19","author":"S Safe","year":"2021","unstructured":"Safe S, Karki K (2021) The paradoxical roles of orphan nuclear receptor 4A (NR4A) in cancer. Mol Cancer Res 19(2):180\u2013191. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0707","journal-title":"Mol Cancer Res"},{"issue":"12","key":"5085_CR209","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B (2021) PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol 18(12):809\u2013823. https:\/\/doi.org\/10.1038\/s41569-021-00569-6","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"5085_CR210","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.bbalip.2016.09.003","volume":"1861","author":"O Amber-Vitos","year":"2016","unstructured":"Amber-Vitos O, Chaturvedi N, Nachliel E, Gutman M, Tsfadia Y (2016) The effect of regulating molecules on the structure of the PPAR-RXR complex. Biochim Biophys Acta 1861(11):1852\u20131863. https:\/\/doi.org\/10.1016\/j.bbalip.2016.09.003","journal-title":"Biochim Biophys Acta"},{"issue":"6785","key":"5085_CR211","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/35013000","volume":"405","author":"S Kersten","year":"2000","unstructured":"Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405(6785):421\u2013424. https:\/\/doi.org\/10.1038\/35013000","journal-title":"Nature"},{"issue":"7220","key":"5085_CR212","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature07413","volume":"456","author":"V Chandra","year":"2008","unstructured":"Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP et al (2008) Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 456(7220):350\u2013356. https:\/\/doi.org\/10.1038\/nature07413","journal-title":"Nature"},{"issue":"1","key":"5085_CR213","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.febslet.2007.11.016","volume":"582","author":"J Sonoda","year":"2008","unstructured":"Sonoda J, Pei L, Evans RM (2008) Nuclear receptors: decoding metabolic disease. FEBS Lett 582(1):2\u20139. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.016","journal-title":"FEBS Lett"},{"issue":"16","key":"5085_CR214","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3390\/cells11162569","volume":"11","author":"P Przybycien","year":"2022","unstructured":"Przybycien P, Gasior-Perczak D, Placha W (2022) Cannabinoids and PPAR ligands: the future in treatment of polycystic ovary syndrome women with obesity and reduced fertility. Cells 11(16):2569. https:\/\/doi.org\/10.3390\/cells11162569","journal-title":"Cells"},{"key":"5085_CR215","doi-asserted-by":"publisher","first-page":"4714914","DOI":"10.1155\/2022\/4714914","volume":"2022","author":"A Enayati","year":"2022","unstructured":"Enayati A, Ghojoghnejad M, Roufogalis BD, Maollem SA, Sahebkar A (2022) Impact of phytochemicals on PPAR receptors: implications for disease treatments. PPAR Res 2022:4714914. https:\/\/doi.org\/10.1155\/2022\/4714914","journal-title":"PPAR Res"},{"issue":"1","key":"5085_CR216","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2006.11.019","volume":"253","author":"XC Xu","year":"2007","unstructured":"Xu XC (2007) Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett 253(1):14\u201324. https:\/\/doi.org\/10.1016\/j.canlet.2006.11.019","journal-title":"Cancer Lett"},{"key":"5085_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2014.12.003","volume":"41","author":"A di Masi","year":"2015","unstructured":"di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C et al (2015) Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med 41:1\u2013115. https:\/\/doi.org\/10.1016\/j.mam.2014.12.003","journal-title":"Mol Aspects Med"},{"issue":"8","key":"5085_CR218","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1073\/pnas.1621425114","volume":"114","author":"DY Lee","year":"2017","unstructured":"Lee DY, Lin TE, Lee CI, Zhou J, Huang YH, Lee PL et al (2017) MicroRNA-10a is crucial for endothelial response to different flow patterns via interaction of retinoid acid receptors and histone deacetylases. Proc Natl Acad Sci U S A 114(8):2072\u20132077. https:\/\/doi.org\/10.1073\/pnas.1621425114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"5085_CR219","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2174\/1568026616666160617072521","volume":"17","author":"M Dominguez","year":"2017","unstructured":"Dominguez M, Alvarez S, de Lera AR (2017) Natural and structure-based RXR ligand scaffolds and their functions. Curr Top Med Chem 17(6):631\u2013662. https:\/\/doi.org\/10.2174\/1568026616666160617072521","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"5085_CR220","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/med.21578","volume":"39","author":"NR de Almeida","year":"2019","unstructured":"de Almeida NR, Conda-Sheridan M (2019) A review of the molecular design and biological activities of RXR agonists. Med Res Rev 39(4):1372\u20131397. https:\/\/doi.org\/10.1002\/med.21578","journal-title":"Med Res Rev"},{"issue":"4","key":"5085_CR221","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1210\/endo.136.4.7895689","volume":"136","author":"A Sugawara","year":"1995","unstructured":"Sugawara A, Yen PM, Qi Y, Lechan RM, Chin WW (1995) Isoform-specific retinoid-X receptor (RXR) antibodies detect differential expression of RXR proteins in the pituitary gland. Endocrinology 136(4):1766\u20131774. https:\/\/doi.org\/10.1210\/endo.136.4.7895689","journal-title":"Endocrinology"},{"issue":"1","key":"5085_CR222","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","volume":"157","author":"RM Evans","year":"2014","unstructured":"Evans RM, Mangelsdorf DJ (2014) Nuclear receptors, RXR, and the big bang. Cell 157(1):255\u2013266. https:\/\/doi.org\/10.1016\/j.cell.2014.03.012","journal-title":"Cell"},{"issue":"1","key":"5085_CR223","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cancers3010198","volume":"3","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Wang L (2011) Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer. Cancers (Basel) 3(1):198\u2013212. https:\/\/doi.org\/10.3390\/cancers3010198","journal-title":"Cancers (Basel)"},{"key":"5085_CR224","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0074-7696(07)61003-1","volume":"261","author":"YS Lee","year":"2007","unstructured":"Lee YS, Chanda D, Sim J, Park YY, Choi HS (2007) Structure and function of the atypical orphan nuclear receptor small heterodimer partner. Int Rev Cytol 261:117\u2013158. https:\/\/doi.org\/10.1016\/S0074-7696(07)61003-1","journal-title":"Int Rev Cytol"},{"issue":"23","key":"5085_CR225","doi-asserted-by":"publisher","first-page":"14398","DOI":"10.1074\/jbc.273.23.14398","volume":"273","author":"HK Lee","year":"1998","unstructured":"Lee HK, Lee YK, Park SH, Kim YS, Park SH, Lee JW et al (1998) Structure and expression of the orphan nuclear receptor SHP gene. J Biol Chem 273(23):14398\u201314402. https:\/\/doi.org\/10.1074\/jbc.273.23.14398","journal-title":"J Biol Chem"},{"issue":"4","key":"5085_CR226","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cell.2006.06.049","volume":"126","author":"AL Bookout","year":"2006","unstructured":"Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126(4):789\u2013799. https:\/\/doi.org\/10.1016\/j.cell.2006.06.049","journal-title":"Cell"},{"issue":"14","key":"5085_CR227","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/sj.emboj.7600728","volume":"24","author":"K Boulias","year":"2005","unstructured":"Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I (2005) Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J 24(14):2624\u20132633. https:\/\/doi.org\/10.1038\/sj.emboj.7600728","journal-title":"EMBO J"},{"key":"5085_CR228","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fimmu.2013.00148","volume":"4","author":"M Kongsbak","year":"2013","unstructured":"Kongsbak M, Levring TB, Geisler C, von Essen MR (2013) The vitamin d receptor and T cell function. Front Immunol 4:148. https:\/\/doi.org\/10.3389\/fimmu.2013.00148","journal-title":"Front Immunol"},{"issue":"4","key":"5085_CR229","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/00041552-199507000-00003","volume":"4","author":"CH Hsu","year":"1995","unstructured":"Hsu CH, Patel SR (1995) Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: calcitriol receptor interaction with its target gene in renal failure. Curr Opin Nephrol Hypertens 4(4):302\u2013306. https:\/\/doi.org\/10.1097\/00041552-199507000-00003","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1\u20132","key":"5085_CR230","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2006.02.016","volume":"371","author":"JM Valdivielso","year":"2006","unstructured":"Valdivielso JM, Fernandez E (2006) Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 371(1\u20132):1\u201312. https:\/\/doi.org\/10.1016\/j.cca.2006.02.016","journal-title":"Clin Chim Acta"},{"issue":"9","key":"5085_CR231","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.3390\/ijms19092663","volume":"19","author":"M Medrano","year":"2018","unstructured":"Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA (2018) Vitamin D: effect on haematopoiesis and immune system and clinical applications. Int J Mol Sci 19(9):2663. https:\/\/doi.org\/10.3390\/ijms19092663","journal-title":"Int J Mol Sci"},{"key":"5085_CR232","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-030-46227-7_4","volume":"1268","author":"P Gnagnarella","year":"2020","unstructured":"Gnagnarella P, Raimondi S, Aristarco V, Johansson HA, Bellerba F, Corso F et al (2020) Vitamin d receptor polymorphisms and cancer. Adv Exp Med Biol 1268:53\u2013114. https:\/\/doi.org\/10.1007\/978-3-030-46227-7_4","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"5085_CR233","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/ibd\/izy092","volume":"24","author":"D Bakke","year":"2018","unstructured":"Bakke D, Sun J (2018) Ancient nuclear receptor VDR with new functions: microbiome and inflammation. Inflamm Bowel Dis 24(6):1149\u20131154. https:\/\/doi.org\/10.1093\/ibd\/izy092","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"5085_CR234","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/j.1464-410X.2008.07509.x","volume":"101","author":"ME Taplin","year":"2008","unstructured":"Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M et al (2008) A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 101(9):1084\u20131089. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07509.x","journal-title":"BJU Int"},{"key":"5085_CR235","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/845340","volume":"2015","author":"E Frohlich","year":"2015","unstructured":"Frohlich E, Wahl R (2015) Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int 2015:845340. https:\/\/doi.org\/10.1155\/2015\/845340","journal-title":"Biomed Res Int"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-023-05085-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:23:34Z","timestamp":1707456214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-023-05085-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":235,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5085"],"URL":"https:\/\/doi.org\/10.1007\/s00018-023-05085-z","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"78"}}